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Abstract
Background: Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of
antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with
once-daily compared to twice-daily dosing in diverse areas of the world.
Methods and Findings: 1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned
with equal probability to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV),
atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil
fumarate (DF) (EFV+FTC-TDF). ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the
upper one-sided 95% confidence bound for the hazard ratio (HR) was #1.35 when 30% of participants had treatment
failure. An independent monitoring board recommended stopping study follow-up prior to accumulation of 472
treatment failures. Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95
treatment failures (18%) among 526 participants versus 98 failures among 519 participants (19%; HR 0.95, 95% CI 0.72–1.27;
p=0.74). Safety endpoints occurred in 243 (46%) participants assigned to EFV+FTC-TDF versus 313 (60%) assigned to
EFV+3TC-ZDV (HR 0.64, CI 0.54–0.76; p,0.001) and there was a significant interaction between sex and regimen safety (HR
0.50, CI 0.39–0.64 for women; HR 0.79, CI 0.62–1.00 for men; p=0.01). Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a
median follow-up of 81 wk there were 108 failures (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%)
among 519 participants assigned to EFV+3TC-ZDV (HR 1.51, CI 1.12–2.04; p=0.007).
Conclusion: EFV+FTC-TDF had similar high efficacy compared to EFV+3TC-ZDV in this trial population, recruited in diverse
multinational settings. Superior safety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are
advantageous for use of this regimen for initial treatment of HIV-1 infection in resource-limited countries. ATV+DDI+FTC had
inferior efficacy and is not recommended as an initial antiretroviral regimen.
Trial Registration: http://www.ClinicalTrials.gov NCT00084136
Please see later in the article for the Editors’ Summary.
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Increased effectiveness of HIV-1 treatment through optimizing
antiretroviral regimens for simplification and reduced toxicity is a
priority in the recent UNAIDS Treatment 2.0 initiative [1,2].
Treatment 2.0 emphasizes that effective antiretroviral regimens
with simplified dosing, fewer side effects, and lower long-term
toxicity are needed to minimize requirements for laboratory
monitoring and maximize the efficiency of antiretroviral delivery.
However, most existing knowledge of antiretroviral safety and
efficacy comes from clinical trials in high-income countries with
study populations not representative of the global diversity of
people infected with HIV-1. Prospective comparisons of antiret-
roviral efficacy and safety in diverse multinational settings with
representative proportions of women are needed to better inform
the choice of antiretroviral drugs for initial HIV-1 treatment.
World Health Organization (WHO, 2010 revision) guidelines
recommend initiation of antiretroviral therapy with two nucleoside
reverse transcriptase inhibitors (NRTI) (zidovudine [ZDV] or
tenofovir disoproxil fumarate [DF] with lamivudine [3TC] or
emtricitabine [FTC) and a non-nucleoside reverse transcriptase
inhibitor (NNRTI) (efavirenz [EFV] or nevirapine) [3]. Random-
ized clinical trials conducted in developed countries provide
evidence that these regimens are safe and effective [4–6]. Although
a regimen of FTC, tenofovir-DF (TDF), and EFV meets criteria
outlined in Treatment 2.0 including low toxicity and simplified
once-daily dosing, the comparative safety and efficacy of this
regimen in low-resource settings is unknown.
Compared to EFV, the HIV-1 protease inhibitor atazanavir
(ATV) lacks known teratogenicity and is active against NNRTI-
resistant virus. These features are potentially advantageous for use
of ATV in resource-limited settings where use of single dose
nevirapine for prevention of mother-to-child transmission of HIV-
1 could increase the risk of NNRTI-resistant virus in women and
their sexual partners. Previous studies of antiretroviral naı ¨ve
persons provide evidence that ATV without ritonavir boosting is
safe and efficacious: Unboosted ATV had similar efficacy
compared to EFV when given with co-formulated 3TC-ZDV
[7], similar efficacy compared to ritonavir-boosted ATV when
given with extended release stavudine and 3TC [8], and
comparable activity to nelfinavir when given with didanosine
and stavudine [9]. Previous studies also provide evidence that,
when given with EFV, the NRTI combination of didanosine and
FTC (or 3TC) is safe and efficacious and has comparable activity
to 3TC-ZDV and stavudine plus 3TC [10–14]. Thus, taken
together available data predict that a regimen of ATV, didanosine,
and FTC would have antiviral efficacy comparable to 3TC-ZDV
and EFV; however, direct comparisons of these two regimens have
not been performed previously.
Methods
Study Design and Participants
The Prospective Evaluation of Antiretrovirals in Resource
Limited Settings (PEARLS) study of the AIDS Clinical Trials
Group (ACTG) evaluated two hypotheses: (1) Antiretroviral
regimens administered once daily are non-inferior to twice-daily
regimens; (2) A regimen containing ATV administered once daily
without ritonavir boosting is non-inferior to an EFV-based
regimen. Study design details are available at ClinicalTrials.gov
NCT00084136 and in the study protocol provided in Text S1.
The CONSORT checklist used for preparation of this manuscript
is provided in Text S2.
Enrollment was limited to the following ACTG international
sites: Instituto de Pesquisa Clinica Evandro Chagas, Rio de
Janeiro, Brazil; Hospital Nossa Senhora da Conceicao-GHC,
Porto Alegre, Brazil; Les Centres GHESKIO, Port-au-Prince,
Haiti; YRG Centre for AIDS Research & Education, Chennai,
India; National AIDS Research Institute, Pune, India; College of
Medicine Clinical Research Site, Blantyre, Malawi; Kamuzu
Central Hospital, Lilongwe, Malawi; Asociacion Civil Impacta
Salud y Educacion - Miraflores and San Miguel Clinical Research
Site, Lima, Peru; Durban Adult HIV Clinical Research Site,
Durban, South Africa; University of Witwatersrand Clinical HIV
Research Unit, Johannesburg, South Africa; Research Institute for
Health Sciences, Chiang Mai, Thailand; and Parirenyatwa
Hospital Clinical Research Center, Harare, Zimbabwe. All ACTG
sites in the United States were also eligible to enroll participants.
Enrollment in the US was limited to no more than 18% of total;
the remaining enrollment was distributed equally across the
international sites with an option for international sites to request
additional enrollment once their initial quota of 100 participants
was filled.
Eligible participants were $18 y, had documented HIV-1
infection, CD4+ lymphocytes ,300 cells/ml, and #7d o f
cumulative antiretroviral therapy prior to study entry. Persons
with absolute neutrophils ,750/ml, hemoglobin ,7.5 g/dl,
calculated creatinine clearance ,60 ml/min, or aspartate trans-
aminase or alanine transaminase greater than 5-fold above the
upper limit of normal were excluded. Women of reproductive
potential were non-pregnant and, if participating in sexual activity
that could lead to pregnancy, agreed to use contraception (two
forms if taking EFV). Persons with serious chronic, acute, or
recurrent infections had completed $14 d of therapy and were
clinically stable.
Randomization
Sites enrolled participants through a centralized web-based
system. The ACTG Data Management Center (Frontier Science
& Technology Research Foundation) randomly assigned partici-
pants 1:1:1 to an open-label regimen of EFV 600 mg daily plus co-
formulated 3TC-ZDV 150 mg/300 mg twice daily (EFV+3TC-
ZDV); or ATV 400 mg once daily with food, plus didanosine-EC
(DDI) 400 mg once daily taken on an empty stomach 1 h before
or 2 h after the ATV dose, plus FTC 200 mg once daily
(ATV+DDI+FTC); or EFV 600 mg once daily plus co-formulated
FTC-TDF 200 mg/300 mg once daily (EFV+FTC-TDF). Per-
muted block randomization was stratified by country (nine levels)
and screening plasma HIV-1 RNA (,100,000 versus $100,000
copies/ml). Treatment assignment was revealed after successful
enrolment at the local site on the web-based system.
Procedures
A targeted physical exam, medication review, adherence
interview and pill counts, serum chemistries, liver function tests,
pregnancy test, CD4+ lymphocyte count, and plasma HIV-1 RNA
were scheduled at least every 8 wk. All study drug modifications
including initial doses, participant-initiated and/or protocol-
mandated interruptions, substitutions, and permanent discontin-
uation and reasons for modification were assessed at each visit.
Adverse events (signs, symptoms, and laboratory results) used US
Division of AIDS (DAIDS) scale for severity grading [15].
Diagnosis criteria were standardized across sites using ACTG
Appendix 60 (see Text S3). Plasma HIV-1 RNA was measured in
real time by the Roche Amplicor Monitor assay (v1.5) at
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Outcomes
The primary efficacy endpoint (treatment failure) was time from
randomization to first occurrence of any of the following: (1) death;
(2) HIV-1 disease progression defined as new or recurrent WHO
stage 4 diagnosis (excluding HIV-1-associated nephropathy or
cardiomyopathy) [3], Chagas’ diseases, or chronic microsporidiosis
or cyclosporidiosis occurring at least 12 wk following randomiza-
tion and not part of immune reconstitution inflammatory
syndrome (IRIS); or (3) virologic failure defined as two successive
measurements of plasma HIV-1 RNA$1,000 copies/ml, with the
first measurement at the week 16 visit or later ($14 wk after
randomization), regardless of study treatment history or status
(intention-to-treat). Participants who did not meet primary
endpoint criteria at any time were censored at the last study visit
at which plasma HIV-1 RNA was measured. Disease progression
and IRIS events were reviewed and adjudicated by a panel of five
physician team members who were blinded to participant identity,
clinic site, demographic characteristics, and study treatment.
Study treatment information was also ignored for the mortality
and HIV-1 disease progression components, so the analysis for the
primary efficacy endpoint was fully intent-to-treat. A post hoc
sensitivity analysis that explored whether crossover could explain
observed results was also performed.
The primary safety endpoint was the earliest of the following
times: date of onset of grade $3 (at least one grade higher than
entry) sign/symptom, date of specimen collection of a grade $3 (at
least one grade higher than entry) laboratory abnormality, or date
of last dose of randomized study treatment before any modifica-
tion to that treatment (change in drug dosage, addition of another
antiretroviral drug, or discontinuation of any component of the
randomized antiretroviral regimen). Elevated serum bilirubin
concentration was excluded from the laboratory abnormality
component of this endpoint only, because it is usually asymptom-
atic and not associated with known adverse outcomes. Any signs,
symptoms, or changes in antiretroviral therapy that resulted from
elevated bilirubin were captured in the other components of the
composite safety endpoint. Participants who did not meet the
safety endpoint definition were censored at the earlier of the last
study visit or final medication dose. Because study treatment
modification was part of the composite primary safety endpoint,
this analysis was necessary as-treated.
First antiretroviral regimen discontinuation was time to
premature discontinuation of study participation, failure to take
antiretrovirals for $8 consecutive wk, or switch to another
antiretroviral regimen. Prespecified antiretroviral substitutions not
included in the definition of regimen discontinuation were as
follows: Substitutions of stavudine for ZDV were not counted as
endpoints in this analysis because WHO guidelines (2003 revision)
when PEARLS was implemented listed 3TC-ZDV as the initial
recommendation for the nucleoside analog component of an
antiretroviral regimen with substitution of other nucleosides,
including stavudine, if needed. In 2006 the protocol was modified
to include TDF for ZDV as a prespecified non-endpoint in
response to the 2006 revision of the WHO guidelines that listed
ZDV and TDF as the preferred initial nucleoside analog reverse
transcriptase inhibitors to be combined with 3TC or FTC.
Substitutions of DDI for TDF and TDF for DDI were not counted
as endpoints because both drugs are once daily nucleoside analogs.
Likewise, substitutions of nevirapine for EFV were prespecified as
non-endpoints because both drugs are in the NNRTI class and can
be dosed once daily.
Plasma HIV-1 RNA below lower quantitation limit (,400
copies/ml) was a secondary endpoint that used the closest value to
the scheduled visit. Another secondary endpoint, time to loss of
virologic response (TLOVR) included an analysis as specified in
US Food and Drug Administration (FDA) guidelines where all
antiretroviral substitutions were counted as endpoints [16], and an
analysis where the prespecified antiretroviral substitutions did not
count as endpoints. Immunologic failure was defined as CD4+
lymphocytes ,100 cells/ml at 48 wk or later. Those not meeting
the immunologic failure secondary endpoint were censored at the
study visit week of last CD4+ lymphocyte count.
Sample Size
Assumptions included a non-inferiority threshold hazard
(relative risk ratio) of 1.35, overall 30% treatment failure rate
within the two arms compared under the alternative of equiva-
lence (hazard ratio [HR]=1.0), and one-sided significance #0.05.
The estimated statistical power for the primary efficacy compar-
ison by a one-sided log-rank test comparison of ATV and
EFV+FTC-TDF arms to EFV+3TC-ZDV was 80% for a sample
size of 456 per arm with inflation by 10% to account for losses to
follow-up. The study did not have a fixed follow-up duration, but
was planned to continue until 30% of participants experienced a
primary efficacy endpoint.
Study Oversight and Monitoring
The study was approved by the institutional review boards and
ethics committees at each participating institution. Written,
informed consent was obtained from study participants, and
human experimentation guidelines of the US Department of
Health and Human Services were followed.
The US National Institute of Allergy and Infectious Diseases
(NIAID) Multinational Data Safety Monitoring Board (DSMB)
reviewed safety and efficacy at least yearly. The prespecified
stopping guidelines were only for early evidence of inferiority of an
experimental arm, based upon Haybittle-Peto bounds. On 6 May
2008, ATV+DDI+FTC was found to be inferior to EFV+3TC-
ZDV for the primary efficacy endpoint at median follow-up of
72 wk. The HR for time to regimen failure was 1.67 (99.98% CI
1.0–2.75; p=0.001), reflecting 104 failures in the ATV+D-
DI+FTC arm compared to 67 failures in the EFV+3TC-ZDV
arm. These CIs reflect those data available at interim review by
the DSMB, which prespecified 99.98% intervals to correspond to
p=0.001 Haybittle-Peto bounds for superiority (and likewise,
inferiority). Study participants, investigators, institutional review
boards, and ethics committees were informed of the DSMB
findings on 23 May 2008, and participants still taking ATV+D-
DI+FTC were switched to alternative antiretroviral regimens. The
DSMB did not report any findings related to the comparison of the
EFV+FTC-TDF and EFV+3TC-ZDV arms so these arms were
not modified and the investigators remained blinded to outcomes
in those arms until completion of all study follow-up.
On 3 November 2009, the DSMB concluded that the
remarkably low rate of new endpoints in the EFV+FTC-TDF
and EFV+3TC-ZDV arms made it unlikely that the study would
reach the planned 30% rate of primary endpoint within 2 y (or
even considerably longer) and continuation of study follow-up for
two more years would likely improve precision of the comparison
by only a small amount. The DSMB recommended that ‘‘it was
simply not practical to continue until 274 events (30%) and that no
statistical penalty needed to be paid for stopping before then.’’ The
ACTG followed the DSMB recommendations and closeout visits
were conducted between 1 April and 31 May 2010.
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Analyses for the comparison of ATV+DDI+FTC to EFV+3TC-
ZDV used data collected from 1 May 2005 through 22 May 2008.
Analyses for comparison of EFV+FTC-TDF to EFV+3TC-ZDV
used data collected through 31 May 2010. The study was designed
to test the primary efficacy hypothesis of non-inferiority using an
upper bound of a one-sided, 0.05 level interval. Early study closure
prompted a revised analysis plan for pairwise comparison. Since
comparison of the ATV+DDI+FTC and EFV+3TC-ZDV arms
used additional data collected between 4 March to 22 May 2008,
two-sided 95% CIs and associated p-values are presented here. As
the closure of the EFV+FTC-TDF and EFV+3TC-ZDV arms was
not due to the prespecified stopping guidelines, we followed the
DSMB recommendations on significance level and focused
inferential procedure for the primary efficacy outcome on
estimating treatment difference effect size and its related range
of plausible values, rather than hypothesis testing. Specifically,
two-sided 95% CIs for treatment difference (parameterized as the
relative difference by HR) were provided. Parallel methods were
used for secondary efficacy outcomes (for consistency) and safety
outcomes (by original plan). p-Values based upon stratified log-
rank test with a null hypothesis of no difference between
randomized arms were provided only for secondary efficacy and
safety outcomes. Time-to-event outcome distributions were
summarized by the method of Kaplan and Meier, and compared
between randomized groups by log-rank test stratified by
randomized allocation. HRs were estimated from Cox propor-
tional hazards regression; HR variation over time was based on a
test for interaction between treatment group and time. Cumulative
probabilities of time-to-event endpoints used Greenwood estimates
of variation for CI formulation. For each of the primary efficacy
and safety time-to-event outcomes, the proportional hazards
assumption was tested through introducing an interaction term
between treatment group and time, and was not rejected in any
case (all p.0.18). Interactions between study treatment and
pretreatment covariates were tested individually by Cox regres-
sion. Estimated binomial proportions were compared between
arms using Fisher exact test and 95% exact CIs. Comparisons of
CD4+ cells over time used a one-sided, 0.025-level Wei-Johnson
test [17].
Results
Study Participants
Between May 2005 and July 2007, 1,571 participants were
randomized to one of the three treatment arms (Figure 1): Brazil
(n=31), Haiti (n=100), India (n=255), Malawi (n=221), Peru
(n=134), South Africa (n=210), Thailand (n=100), US (n=210),
and Zimbabwe (n=110). There were 739 women (47%) and 787
(50%) participants were Black or African American. There were
434 ongoing infections at study entry (Table S1) that were treated
according to local standard of care. The five most common
ongoing infections were oropharyngeal candidiasis (77 cases),
pulmonary tuberculosis (73 cases), mucocutaneous herpes simplex
virus (65 cases), anogenital warts (56 cases), and other or
vulvovaginal candidiasis (44 and 32 cases, respectively). Together,
these six diagnoses accounted for 80% of the ongoing infections at
study entry.
Follow-up
Outcomes are summarized in Figure 1; 99% of expected study
visits were completed. Median follow-up was 81 wk for compar-
ison of ATV+DDI+FTC to EFV+3TC-ZDV and 184 wk for the
comparison of EFV+FTC-TDF to EFV+3TC-ZDV. There were
47 deaths (3%) and 183 (12%) participants did not complete study
follow-up; 126 (8%) left prior to regimen failure. The risk ratio of
any premature study discontinuation for participants allocated to
ATV+DDI+FTC versus EFV+3TC-ZDV was 0.80 (CI 0.54–1.18;
p=0.26) and for EFV+FTC-TDF versus EFV+3TC-ZDV was
0.79 (CI 0.59–1.06; p=0.12). The primary endpoint analyses
included all 1,571 participants according to randomized treatment
assignment.
Efficacy of ATV Plus DDI and FTC
Risk of treatment failure primary endpoint was greater for
participants assigned to ATV+DDI+FTC compared to
EFV+3TC-ZDV with 108 (20.5%) versus 76 (14.6%) failures,
respectively (Table 1). The between-arm difference in primary
endpoint failure rates persisted over time (Figure 2A). The most
common cause of treatment failure was confirmed plasma HIV-1
RNA $1,000 copies/ml (82% of primary endpoints). The lower
bounds of the 95% CIs for the relative hazard of both treatment
and virologic failure, but not disease progression and death, for
comparison of the ATV and EFV+3TC-ZDV arms excluded 1.0
(Table 1). 30 disease progression events (15 in the ATV+D-
DI+FTC arm and 15 in the EFV+3TC/ZDV arm) did not meet
the definition of treatment failure because of either being
diagnosed within the first 12 wk of study follow-up (15 events)
and/or being part of an IRIS event (15 events). Men randomized
to ATV+DDI+FTC had higher risk of treatment failure compared
to men randomized to EFV+3TC-ZDV (HR 2.14, CI 1.42–3.42)
but a difference in regimen efficacy was not detected in women
(Figure 3A, left side). No significant statistical interactions between
treatment effect and race and ethnicity, country, or viral load
stratum were observed.
Plasma HIV-1 RNA was below 400 copies/ml in 82% of
participants randomized to ATV+DDI+FTC versus 88% ran-
domized to EFV+3TC-ZDV at 24 wk (p=0.004) (Figure 2C). In
the FDA TLOVR analysis disallowing any antiretroviral substi-
tution, there was no difference between treatment arms at 48 wk
(135 versus 149; p=0.3). In the TLOVR analysis that did not
penalize for prespecified antiretroviral drug substitutions, the
number of endpoints was greater for ATV+DDI+FTC compared
to EFV+3TC-ZDV at 48 wk (135 versus 85; p,0.001).
Risk of immunologic failure was low and did not differ between
arms (Table 1). CD4+ lymphocyte increases from baseline were
187/ml and 152/ml in the ATV+DDI+FTC and EFV+3TC-ZDV
arms, respectively, at 48 wk and were significantly greater in
ATV+DDI+FTC at all time points evaluated (all individual p-
values,0.05; one-sided test over 96 wk, p,0.001) (Figure 2E).
Regimen Discontinuation for ATV Plus DDI and FTC
Initial antiretroviral regimen discontinuation was due to non-
prespecified drug substitutions (61% of all observed discontinua-
tions), premature discontinuation of study follow-up (30%),
permanent discontinuation of all antiretroviral therapy (8%), and
temporary discontinuation of all antiretroviral therapy for more
than 8 wk (1%). Risk of this endpoint, when protocol-specified
drug substitutions were not counted, was significantly greater
among participants randomized to ATV+DDI+FTC (Table 1).
The most common reasons for non-prespecified drug substitutions
among persons randomized to ATV+DDI+FTC were virologic
failure (40 cases), tuberculosis treatment (28 cases), clinical adverse
events (23 cases), and laboratory abnormalities (10 cases).
Safety of ATV Plus DDI and FTC
Excluding hyperbilirubinemia, which is an expected effect of
ATV treatment, there were fewer safety endpoints among
Evaluation of Antiretrovirals in Diverse Settings
PLOS Medicine | www.plosmedicine.org 5 August 2012 | Volume 9 | Issue 8 | e1001290Figure 1. Flow diagram for participant outcomes. The outcomes of all participants randomized to the three arms are provided. The most
common prior antiretroviral exposure was for prevention of mother-to-child transmission of HIV-1 with either ZDV monotherapy (19 women; median
duration 32 d; intraquartile range 30–60 d) or a single dose of nevirapine in the peripartum period (16 women). Continuous variable values are the
median for the treatment arm. Creatinine clearance was calculated by Crockoft-Gault equation. Follow-up visits were conducted for 1,571
participants. ATV plus FTC and DDI follow-up was terminated on 22 May 2008 in response to the DSMB recommendation and comparison of ATV plus
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EFV+3TC-ZDV (Figure 2G; Table 1). Estimated probability of
a safety endpoint by week 48 was 32.6% (CI 28.8%–36.8%) versus
42.3% (CI 38.2–46.7%). There was a significant interaction
between study treatment and both sex and plasma HIV-1 RNA
strata for the primary safety endpoint (p=0.01 for both) (Figure 3B,
left side). Women randomized to ATV+DDI+FTC had lower risk
of a safety endpoint compared to women randomized to
EFV+3TC-ZDV (HR 0.56, CI 0.42–0.74). Among men, risk
difference for the primary safety endpoint between arms was
attenuated (HR 0.92, CI 0.71–1.19). The risk of a safety endpoint
for the lower versus the upper plasma HIV-1 RNA strata were
0.55 (CI 0.41–0.73) and 0.89 (CI 0.70–1.15), respectively. There
were no significant interactions between race or country and
assigned treatment for the primary safety endpoint.
There were fewer initial dose modifications among participants
randomized to ATV+DDI+FTC compared to EFV+3TC-ZDV
(Table 1). The estimated cumulative probability of any dose
modification of the assigned antiretroviral regimen at 48 wk was
20.7% (CI 17.5%–24.4%) compared to 25.7% (CI 22.1%–29.7%),
respectively. Excluding hyperbilirubinemia, there were fewer
severe or potentially life-threatening laboratory abnormalities in
ATV+DDI+FTC (Tables 1 and S3); the estimated cumulative
probability at 48 wk was 12.4% (CI 9.9%–15.6%) compared to
21.0% (CI 17.7%–24.8%). There was a lower risk of a severe or
life-threatening sign or symptom in the ATV+DDI+FTC arm
(Tables 1 and S4). At 48 wk the cumulative probabilities of a new
severe or life-threatening sign or symptom were 10.5% (CI 8.1%–
13.4%) and 16.5% (CI 13.5%–20.0%) for the ATV+DDI+FTC
and EFV+3TC-ZDV arms, respectively.
Neurological symptoms, cachexia/weight loss, and dermatolog-
ic symptoms occurred in 13 (2%), 5 (1%), and 8 (2%) participants
assigned to ATV+DDI+FTC, respectively, compared to 22 (4%),
17 (3%), and 15 (3%) participants assigned to EFV+3TC-ZDV
(Table S3). Participants assigned to ATV+DDI+FTC were more
likely to have a new diagnosis of serious renal disease (19 [4%]
versus 5 [1%] participants; nominal p=0.006) (Tables S5 and S6).
Efficacy of EFV+FTC-TDF
There were 95 (18.0%) and 98 (18.8%) treatment failures in
the EFV+FTC-TDF and EFV+3TC-ZDV arms, respectively,
and the range of the relative risk difference was 0.72 to 1.27
(Table 2). Treatment failure relative risk did not change
significantly over time (p=0.9) (Figure 2B). There were no
FTC and DDI to EFV plus 3TC-ZDV used data available up to the time of the ATV arm closure (red box); median follow-up 81 wk. Comparison of EFV
plus FTC-TDF to EFV plus 3TC-ZDV used all follow-up data for participants in these arms through 31 May 2010 (green box); median follow-up 184 wk.
doi:10.1371/journal.pmed.1001290.g001
Table 1. Primary and secondary time-to-event outcomes for the comparison of atazanavir plus didanosine-EC and emtricitabine to
efavirenz plus lamivudine-zidovudine using data collected through 22 May 2008.
Study Endpoint n Events HR (95% CI)
a p-Value
b Events per 100 Person-Years (95% CI)
ATV+DDI+FTC EFV+3TC-ZDV ATV+DDI+FTC EFV+3TC-ZDV
Treatment failure (composite
endpoint)
108 76 1.51 (1.12–2.04) 0.007 13.3 (11.0–16.1) 8.9 (7.1–11.2)
All death
c 9 10 0.88 (0.36–2.17) 0.78 1.0 (0.5–1.9) 1.1 (0.6–2.0)
All initial HIV-1 disease
progression
d,e
18 10 1.80 (0.83–3.90) 0.14 2.0 (1.3–3.2) 1.1 (0.6–2.1)
All initial confirmed virologic
failure
e,f
92 63 1.56 (1.12–2.16) 0.008 11.2 (9.1–13.7) 7.3 (5.7–9.4)
Safety events (composite
endpoint)
e,g
210 252 0.73 (0.60–0.88) 0.001 30.8 (26.9–35.2) 43.0 (38.0–48.6)
All initial antiretroviral dose
modifications
e,h
149 172 0.80 (0.65–1.00) 0.05 9.9 (8.4–11.6) 12.2 (10.5–14.2)
All initial grade 3 or 4 signs or
symptoms
d,e
69 98 0.66 (0.48–0.90) 0.008 8.2 (6.5–10.4) 12.6 (10.3–15.3)
All initial grade 3 or 4 laboratory
abnormalities
d,e,g
76 119 0.58 (0.43–0.78) 0.0003 9.2 (7.3–11.5) 16.1 (13.4–19.3)
First antiretroviral regimen
discontinuation
i
149 103 1.57 (1.22–2.01) 0.0005 9.9 (8.4–11.6) 6.2–(5.1–7.5)
Immunologic failure
j 19 23 0.82 (0.44–1.52) 0.53 2.1 (1.3–3.3) 2.5 (1.7–3.8)
aAlso known as relative risk. Estimated from Cox regression model stratified by both country and RNA stratum and including randomized treatment group as sole
covariate.
bp-Value calculated from stratified log-rank test between arms.
cThe five most common causes of death were infection (six deaths), liver disease (three deaths), malignancy (two deaths), suicide (two deaths), and unknown cause (two
deaths).
dDisease progression diagnoses are in Table S2; grade 3 and 4 laboratory events in Table S3; and signs and symptoms in Table S4.
eAll events meeting these criteria are reported; some participants met criteria for multiple endpoints.
fConfirmed plasma HIV RNA$1,000 copies/ml at study week 16 or later.
gElevated bilirubin concentration not included.
hChange in any component of initial randomized antiretroviral regimen.
iThe following antiretroviral substitutions were prespecified and were not included in this endpoint: TDF for DDI, stavudine or TDF for ZDV, or nevirapine for EFV.
jCD4+ lymphocytes ,100/ml at week 48 or later.
doi:10.1371/journal.pmed.1001290.t001
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PLOS Medicine | www.plosmedicine.org 7 August 2012 | Volume 9 | Issue 8 | e1001290Figure 2. Efficacy and safety of randomized study treatment over time. (A–H) black circles, EFV plus 3TC-ZDV; red triangles, ATV plus DDI-EC
and FTC; green squares, EFV plus FTC-TDF. (A–B) Estimated cumulative probability of antiretroviral regimen failure defined by the protocol-specified
primary efficacy endpoint: comparison of EFV plus 3TC-ZDV to ATV plus FTC and DDI (A) and EFV plus FTC-TDF (B). (C–D) Proportion of participants
with plasma HIV-1 RNA less than 400 copies/ml for comparison of EFV plus 3TC-ZDV to ATV plus FTC and DDI (C) and EFV plus FTC-TDF (D). These
comparisons included all randomized study participants according to assigned study treatment. The analysis that counted missing values as greater
than 400 copies/ml (open symbols) is truncated at the maximum potential duration of study follow-up for participants who entered the study at the
end of the enrollment period (144 wk). (E–F) Median change in CD4+ lymphocyte count from screening value over time for comparison of EFV plus
3TC-ZDV to ATV plus FTC and DDI (E) and EFV plus FTC-TDF (F). (G–H) Estimated cumulative probability a safety endpoint over time for comparison of
EFV plus 3TC-ZDV to ATV plus FTC and DDI (G) and EFV plus FTC-TDF (H). For (A–D, G and H), bars represent the 95% CI for the estimate. For (E–F),
bars represent the interquartile range. (A–H) The number of evaluable participants at each time point is provided for each randomized treatment
assignment.
doi:10.1371/journal.pmed.1001290.g002
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treatment effect and sex, race and ethnicity, country, or viral load
stratum (Figure 3A, right side). The most common cause of
regimen failure was confirmed plasma HIV-1 RNA$1,000
copies/ml (81% of all primary endpoints). The range of the
relative risk difference for virologic failure was 0.72 to 1.36
(Table 2). Of 156 initial virologic failures, 64 (41%) and 125
(80%) occurred within the first 24 wk and 96 wk of follow-up,
respectively. There were no significant differences in the risk of
HIV-1 disease progression or death between arms. 25 disease
progression events (15 in the EFV+FTC/TDF arm and ten in the
EFV+3TC/ZDV arm) did not meet the definition of the
treatment failure endpoint due to either being diagnosed within
the first 12 wk of study follow-up (12 events) and/or being part of
an IRIS event (13 events).
There were no differences between EFV+FTC-TDF and
EFV+3TC-ZDV for plasma HIV-1 RNA,400 copies/ml at 24
and 48 wk (p=0.12 and 0.60, respectively; missing imputed as
$400 copies/ml) and the kinetics of attaining and maintaining
plasma HIV-1 RNA suppression were similar in both arms over
Figure 3. Subgroup analysis for primary efficacy and safety endpoints by randomly assigned antiretroviral treatment. Subgroup
analyses were conducted for the baseline covariates self-reported sex and race/ethnicity and the countries in which the participating research sites
were located. The relative risk and 95% CIs are provided for all participants (overall) and for each subgroup. p-Value represents interaction test
between baseline covariate and randomized treatment group. Comparisons between ATV plus DDI and FTC and EFV plus 3TC-ZDV are in red.
Comparisons between EFV plus FTC-TDF and EFV plus 3TC-ZDV are in green. (A) Treatment failure (efficacy) composite endpoint. (B) Safety events
composite endpoint.
doi:10.1371/journal.pmed.1001290.g003
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antiretroviral substitution there were fewer events in EFV+FTC-
TDF arm at 48 wk (99 versus 153; p,0.001) and 96 wk (124
versus 186; p,0.001). In the TLOVR analysis that did not
penalize for prespecified antiretroviral drug substitutions, there
was no difference between treatment arms at 48 or 96 wk (86
events in each arm, p=0.99 and 111 versus 116 events; p=0.74,
respectively).
Risk of immunologic failure was low (Table 2). Median absolute
CD4+ lymphocytes increased from 167 cells/ml at screening to 452
cells/ml at 192 wk and there was no significant difference between
the EFV+FTC-TDF and EFV+3TC-ZDV arms over time (one-
sided p=0.06) (Figure 2F).
Regimen Discontinuation for EFV+FTC-TDF
Antiretroviral regimen discontinuation was due to non-prespec-
ified drug substitutions (44% of all observed discontinuations),
premature discontinuation of study follow-up (44%), temporary
discontinuation of all antiretroviral therapy for more than 8 wk
(8%), and permanent discontinuation of all antiretroviral therapy
(4%). Risk of this endpoint, when protocol-specified drug
substitutions were not counted, did not differ significantly between
EFV+FTC-TDF and EFV+3TC-ZDV (Table 2). The most
common reasons for non-prespecified drug substitutions among
persons randomized to EFV+FTC-TDF and EFV+3TC-ZDV
were virologic failure (44 versus 40 cases), clinician/participant
decision (seven cases each), and pregnancy (seven cases each).
Safety of EFV+FTC-TDF
There were fewer safety endpoints among participants assigned
to EFV+FTC-TDF compared to EFV+3TC-ZDV (Table 2).
Estimated probability of a safety endpoint by week 192 was 45.5%
(CI 41.3%–50.0%) versus 61.5% (CI 57.1%–65.9%). Relative risk
of a safety endpoint between arms did not vary over time (p=0.8)
(Figure 2H). There was a significant interaction between sex and
study treatment for the primary safety endpoint (Figure 3B, right
side). Women randomized to EFV+FTC-TDF had lower risk of a
safety endpoint compared to women randomized to EFV+3TC-
ZDV (HR 0.50, CI 0.39–0.64). Among men, risk difference for the
primary safety endpoint between arms was attenuated (HR 0.79,
CI 0.62–1.00). There were no significant interactions between
race, country, or entry plasma HIV-1 RNA stratum and assigned
treatment arm for the primary safety endpoint (Figure 3B, right
side).
Among the individual safety endpoint components, there were
significantly fewer initial dose modifications among participants
randomized to EFV+FTC-TDF compared to EFV+3TC-ZDV
(Table 2). The estimated cumulative probability of any dose
modification of the assigned treatment arms at 192 wk was 25.9%
(CI 22.3%–30.0%) compared to 43.9% (CI 39.6%–48.5%),
respectively. At any time prior to meeting the primary efficacy
endpoint, six (1%) participants assigned to EFV+FTC-TDF
switched to ZDV (not prespecified) and 46 (8.9%) participants
assigned to EFV+3TC-ZDV switched to TDF (prespecified).
Adjustment for effects of crossover from FTC-TDF to 3TC-ZDV
and 3TC-ZDV to FTC-TDF, including risk time and events
during crossover, did not significantly affect the risk ratio estimate
for the primary efficacy comparison (adjusted HR=0.94).
There were fewer severe or potentially life-threatening laboratory
abnormalities in the EFV+FTC-TDF arm compared to the
EFV+3TC-ZDV arm (Tables 2 and S8). The estimated cumulative
probability of a severe or potentially life-threatening laboratory
Table 2. Primary and secondary time-to-event outcomes for comparison of efavirenz plus emtricitabine-tenofovir-DF to efavirenz
plus lamivudine-zidovudine using data collected through 31-May-2010.
Study Endpoint Number of Events
Hazard Ratio (95%
CI)
a p-Value
b
Events per 100 Person-Years (95%
CI)
EFV+FTC-TDF EFV+3TC-ZDV EFV+FTC-TDF EFV+3TC-ZDV
Treatment failure (composite endpoint) 95 98 0.95 (0.72–1.27) NA 5.4 (4.4–6.7) 5.8 (4.7–7.0)
All death
c 18 20 0.90 (0.48–1.70) 0.74 0.9 (0.6–1.5) 1.1 (0.7–1.7)
All initial HIV-1 disease progression
d,e 11 12 0.89 (0.39–2.01) 0.77 0.6 (0.3–1.0) 0.7 (0.4–1.1)
All initial confirmed virologic failure
e,f 78 78 0.99 (0.72–1.36) 0.95 4.4 (3.6–5.5) 4.5 (3.6–5.7)
Safety events (composite endpoint) 243 313 0.64 (0.54–0.76) ,0.0001 17.6 (15.5–19.9) 28.7 (25.7–32.0)
All initial antiretroviral dose modifications
e,g 140 222 0.54 (0.44–0.67) ,0.0001 8.1 (6.9–9.6) 15.6 (13.7–17.8)
All initial grade 3 or 4 signs or symptoms
d,e 115 116 0.96 (0.74–1.24) 0.73 6.9 (5.8–8.3) 7.4 (6.1–8.8)
All initial grade 3 or 4 laboratory
abnormalities
d,e
98 154 0.55 (0.43–0.71) ,0.0001 5.8 (4.8–7.1) 10.8 (9.2–12.6)
First antiretroviral regimen discontinuation
h 125 147 0.83 (0.65–1.05) 0.12 7.1 (5.9–8.4) 8.6 (7.4–10.2)
Immunologic failure
i 33 30 1.08 (0.66–1.79) 0.75 1.8 (1.3–2.5) 1.6 (1.1–2.3)
aAlso known as relative risk. Estimated from Cox regression model stratified by both country and RNA stratum and including randomized treatment group as sole
covariate.
bp-Value calculated from stratified log-rank test between arms. Not applicable (NA) because no formal hypothesis testing was performed based on DSMB
recommendations.
cThe five most common causes of death were infection (17 deaths) and unknown cause (five deaths) followed by suicide, trauma, and stroke (three deaths each).
dDisease progression diagnoses are in Table S7; grade 3 and 4 laboratory adverse events in Table S8; and signs and symptoms in Table S9.
eAll events meeting these criteria are reported; some participants met criteria for multiple endpoints.
fConfirmed plasma HIV RNA$1,000 copies/ml at study week 16 or later.
gChange in any component of initial randomized antiretroviral regimen.
hThe following antiretroviral substitutions were prespecified and were not included in this endpoint: stavudine or TDF for ZDV, nevirapine for EFV, or didansoine for
TDF.
iCD4+ lymphocytes ,100/ml at week 48 or later.
doi:10.1371/journal.pmed.1001290.t002
Evaluation of Antiretrovirals in Diverse Settings
PLOS Medicine | www.plosmedicine.org 10 August 2012 | Volume 9 | Issue 8 | e1001290abnormality at 192 wk was 19.7% (CI 16.4%–23.7%) compared to
30.9% (CI 27.0%–35.2%). Neutropenia was the most common
adverse laboratory abnormality among persons assigned to
EFV+3TC-ZDV, but the risk of laboratory abnormalities between
arms remained significant when neutropenia events were excluded
(HR 0.71, CI 0.52–0.96; p=0.03). There were five severe or
potentially life-threatening elevations of serum creatinine among
participants assigned to EFV+FTC-TDF and two among partici-
pants assigned to EFV+3TC-ZDV. The risk of a severe or life-
threatening sign or symptom was not significantly different between
arms (Tables 2 and S9). Participants assigned to EFV+FTC-TDF
had fewer serious metabolic diagnoses compared to participants
assigned to EFV+3TC-ZDV (three versus 19 cases; p,0.001)
(Tables S10 and S11) with seven diagnoses of lipoatrophy and two
diagnoses of lipoaccumulation in the EFV+3TC-ZDV arm
compared to none in the EFV+FTC-TDF arm.
Co-infection with Mycobacterium tuberculosis
A total of 172 (10.9%) participants were diagnosed with
tuberculosis: 91 participants had active tuberculosis at the time
of study entry and continued tuberculosis treatment during study
follow-up. 81 participants had a new diagnosis of active
tuberculosis after study entry. During study follow-up 28
participants randomized to ATV+DDI+FTC had an initial
antiretroviral drug substitution because of need for anti-tubercu-
losis therapy triggering the antiretroviral regimen switch outcome.
No participants randomized to EFV plus 3TC-ZDV or EFV plus
FTC-TDF had an antiretroviral drug substitution because of anti-
tuberculosis treatment.
Pregnancy
There were 62 pregnancies among 58 women in the trial
population. For the comparison of ATV+DDI+FTC to
EFV+3TC-ZDV there were 20 and eight pregnancies, respective-
ly, and the incidence of pregnancy among women of childbearing
potential was 4.8 per 100 person-years (95% CI 3.1–7.4) versus 1.9
per 100 person-years (95% CI 1.0–3.9). Of these 28 pregnancies,
there were 12 live births, nine spontaneous abortions, five induced
abortions, one intrauterine fetal demise, and one ectopic
pregnancy. For the comparison of EFV+FTC/TDF to
EFV+3TC-ZDV there were 20 and 22 pregnancies, respectively,
and the incidence of pregnancy among women of childbearing
potential was 2.3 per 100 person-years (95% CI 1.5–3.6) versus 2.6
per 100 person-years (95% CI 1.7–3.9). Of these 42 pregnancies,
there were 14 live births, 11 spontaneous abortions, seven induced
abortions, two intrauterine fetal demise, and eight women
remained pregnant at the time of study closure.
Discussion
A unique feature of PEARLS is the prospective enrollment of a
study population from low-, intermediate-, and high-income
countries on four continents with near equal proportions of men
and women. The distribution of enrollment by country, uniform
entry criteria, and quality assurance measures across study sites
allowed direct and highly powered comparisons of antiretroviral
regimen efficacy in HIV-1-infected persons with diverse racial,
cultural, and demographic characteristics. In this context, ATV+D-
DI+FTC had inferior efficacy compared to EFV+3TC-ZDV and is
not recommend as an initial antiretroviral regimen. The regimen of
EFV+FTC-TDF had similar high and durable efficacy with a
significant safety advantage compared to EFV+3TC-ZDV.
PEARLS was the first clinical trial to prospectively evaluate
ATV+DDI+FTC. This regimen had significantly inferior virolog-
ical efficacy as demonstrated by highly significant greater rates of
protocol defined virologic failure (plasma HIV-1 RNA$1,000
copies/ml at week 16 or later) and significantly less viral
suppression (plasma HIV-1 RNA ,400 copies/ml) at 24 wk,
which was a prespecified secondary endpoint. PEARLS was not
designed to directly compare individual antiretroviral agents
within regimens, so the reason for inferiority of this antiretroviral
combination is uncertain. Participants were instructed to take DDI
on an empty stomach at a separate time from when ATV was
taken with food. The possibility that this inconvenient dosing
schedule could have affected adherence to the ATV+DDI+FTC
regimen is being investigated. There was no significant interaction
between treatment effect and baseline viral load stratum for the
comparison of ATV+DDI+FTC to EFV+3TC/ZDV. However,
there was a significant difference in treatment effect between
women and men for the efficacy of ATV+DDI+FTC and the
inferior efficacy of this regimen compared to EFV+3TC-ZDV was
most pronounced among men. Several previous studies demon-
strated higher serum protease inhibitor concentrations among
women [18–20], so we are currently investigating whether
inadequate ATV exposure in men in the ATV+DDI+FTC arm
explains the interaction between sex and treatment efficacy in
PEARLS. Given that women had significantly better relative
efficacy with this regimen than men, whether or not this regimen
should be used for initial treatment of HIV-1-infected women
remains an unanswered question.
Overall, the ATV+DDI+FTC arm had superior safety compared
to EFV+3TC/ZDV. Although absolute number of events was small,
participants assigned to ATV+DDI+FTC had greater frequency of
serious renal disease. Previous large studies in which ATV,
didanosine, and FTC were components of other multidrug
antiretroviral regimens did not report this toxicity [7–14]. Partici-
pants assigned to ATV+DDI+FTC had greater CD4+ lymphocyte
increases than participants in the EFV+3TC/ZDV arm. Since there
was a trend toward more new AIDS endpoints in the ATV arm
compared to the EFV arm (18 versus 10; p=0.14) (see Table 1),
there was no evidence that the statistically significant difference in
CD4+ cell count increase was associated with a clinical benefit.
PEARLS is the second randomized clinical trial to compare
EFV+FTC-TDF and EFV+3TC-ZDV in an initial antiretroviral
regimen. The study populations of the previous study (GS-01-934)
[6] and PEARLS are different. Compared to GS-01-934,
PEARLS had a larger sample size for the comparison of
EFV+FTC-TDF to EFV+3TC-ZDV (1,045 versus 515) and a
larger proportion of women (46% versus 14%), African race (50%
versus 23%), Asian race (23% versus #4%), Hispanic ethnicity
(20% versus 16%), and greater geographic diversity (North
America, Caribbean, South America, Africa and Asia versus North
America and Europe). These differences in study populations, and
their potential effects on study outcomes, should be considered
when comparing the results of GS-01-934 and PEARLS.
A second key finding of PEARLS is that EFV+FTC-TDF and
EFV+3TC-ZDV had very similar treatment failure rates and both
regimens suppressed plasma HIV-1 RNA below 400 copies/ml for
greater than 80% of participants for up to 144 wk. Given the
precision of the confidence bounds on the efficacy comparisons, we
conclude that these regimens had similar efficacy for initial
treatment of HIV-1. GS-01-934 reached different conclusions
about the relative efficacy of these two antiretroviral regimens [6]. It
is possible that differences in the study populations between
PEARLS and GS-01-934 contributed to the different efficacy
conclusions, but the finding that sex, race, ethnicity, or geography
did not affect relative regimen efficacy in PEARLS (Figure 2A, right
panel) does not support this explanation. The conclusion of the GS-
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EFV+3TC-ZDV was based on an FDA TLOVR primary endpoint
that assigned equal consequence to changes in the randomized drug
assignments regardless of the reason for change. When the FDA
TLOVR algorithm was evaluated as secondary endpoint in
PEARLS we also found significant superiority of EFV+FTC-
TDF, but a TLOVR algorithm that did not count protocol-
prespecified drug substitutions as endpoints did not detect a
difference between arms. The discordant findings of the two
TLOVR analyses in PEARLS suggest that the different conclusions
of GS-934 and PEARLS about relative regimen efficacy could be
due to whether or not drug substitutions for toxicity management
were included in the primary efficacy endpoint. Inclusion of drug
discontinuation for toxicity management in an efficacy endpoint has
the potential to lead to inaccurate conclusions about regimen
efficacy. This point is illustrated in the efficacy comparison of
ATV+DDI+FTC to EFV+3TC-ZDV in PEARLS. In the FDA
TLOVR the inferior efficacy of ATV+DDI+FTC was masked by
the higher rate of drug substitutions in the EFV+3TC-ZDV arm,
whereas in PEARLS the primary endpoint comparison and the
TLOVR that did not count protocol-specified drug substitutions
ATV+DDI+FTC had clearly inferior efficacy.
Another important finding of PEARLS is that EFV+FTC-TDF
had superior safety with significantly less laboratory adverse events
compared to EFV+3TC-ZDV. This finding also differs from GS-
01-934, which had overall higher rates of primary safety events
than PEARLS [6], but did not detect a significant difference in
clinical or laboratory adverse events between arms. Since the
better safety of EFV+FTC-TDF in PEARLS was most pro-
nounced in women, we speculate that the larger number of women
in PEARLS allowed us to detect this safety difference.
The between-arm differences in the PEARLS primary safety
analyses were driven largely by higher rates of neutropenia and
anemiaresulting inprotocol-recommendeddrug substitutionsinthe
EFV+3TC-ZDV arm. Neutropenia and anemia are well-described
toxicities of ZDV [21], and neutropenia has been associated with
increased risk of serious bacterial infections in HIV-infected people
[22–25]. Thus the risk, potential consequences and the laboratory
monitoring required to detect and manage neutropenia and anemia
are important considerations when deciding whether to initiate
antiretroviral treatment with EFV+3TC-ZDV. Although no
apparent differences in the occurrence of clinical events as a
complication of neutropenia or anemia were observed in PEARLS,
potential consequences could have been attenuated by frequent
laboratory monitoring and standard procedures for clinical
management of adverse events specified in the protocol. The
findingthat the EFV+FTC-TDF armhad significantly fewerserious
metabolic diagnoses (which included lipoatrophy and lipodystro-
phy) is an important safety advantage of this regimen that was also
observed in GS-01-934 [26]. Although renal impairment has been
associated with TDF, renal adverse events were uncommon in the
EFV+FTC-TDF arm of PEARLS.
All HIV-1 protease inhibitors, even with ritonavir boosting,
have a significant pharmacokinetic interaction with rifampin that
decreases protease inhibitor concentrations and potentially reduc-
es anti-HIV-1 efficacy [3]. Thus use of HIV-1 protease inhibitors
in persons with active tuberculosis is not recommended if other
options are available. Although active tuberculosis was relatively
uncommon in PEARLS participants overall, treatment of tuber-
culosis was the third most common cause of the antiretroviral
regimen discontinuation endpoint in the ATV plus DDI and FTC
arm largely because of the requirement to substitute for ATV if
there was concomitant use of rifampin. There was no prescribed
substitution for EFV if rifampin was used and discontinuation due
to tuberculosis treatment did not occur in either EFV containing
arm.
Half of HIV-1 infections worldwide occur in women [27], but
historically women are underrepresented in clinical trials of
antiretroviral therapy [28]. Almost half of PEARLS participants
were women so we were able to evaluate potential interactions
between sex and treatment effect and safety. Our findings of
greater risk of safety events for women assigned to EFV+3TC-
ZDV and higher relative efficacy of an ATV-based regimen in
women compared to men add to a growing body of evidence that
antiretroviral efficacy and safety can differ in women and men
[29–31], and support further development of sex-specific recom-
mendations for both antiretroviral regimen choice and toxicity
monitoring. When treating HIV-1-infected women with EFV it is
important to recognize the teratogenic risk during the first
trimester of pregnancy. In PEARLS, women of reproductive
potential were treated with EFV only if they agreed to use effective
birth control methods and close monitoring was performed to
detect pregnancies early to ensure that EFV was used safely.
Despite these requirements, there were 62 pregnancies during
study follow-up, including 42 in the two EFV-containing arms. It is
also notable that the incidence of pregnancy of women of child-
bearing potential was higher in the ATV+DDI+FTC arm, which
had less stringent contraception requirements, compared to the
EFV-containing arms. The outcomes of the live births to women
in the PEARLS study are reported elsewhere [32].
There are limitations to consider in the application of the study
findings to resource-limited settings. PEARLS was conducted at
clinical research sites affiliated with academic medical centers in
large cities and these environments are undoubtedly different from
community clinics or rural health care facilities. The entry criteria
resulted in recruitment of a relatively health study population with
a low prevalence of co-morbidities. Although most participants
had a pretreatment CD4+ lymphocyte count that put them at risk
for AIDS-related complications, relatively few reported prior or
current AIDS-related infection or malignancy at baseline. Data
concerning potential participants who were screened and found
not to meet entry criteria were not collected so it is unclear how
representative our study population was of other HIV-1-infected
persons in care at the study sites. Intense clinical and laboratory
monitoring required by the study design could also have affected
safety and efficacy outcomes through improved adherence and
retention in care. To date, we have only investigated the influence
of factors such as race/ethnicity, sex, and geography on treatment
effect (e.g., the performance of one regimen relative to another
regimen). Although we did not detect interactions between race/
ethnicity and geography and treatment effect, this finding does not
mean that these factors do not affect antiretroviral efficacy or
safety and further analyses to explore these possibilities are
ongoing.
To our knowledge, PEARLS is the first study to recruit a study
population with this racial, geographic, and sex diversity for a
prospective randomized clinic trial of antiretroviral therapy. This
unique feature of PEARLS likely contributed to the identification
of previously unrecognized sex-related differences in antiretrovi-
ral efficacy and safety, and provides an evidence base to better
guide the choice of an initial antiretroviral regimen in multina-
tional settings. The efficacy and safety of EFV+FTC-TDF in this
diverse study population, especially in HIV-1-infected women,
combined with the availability of these three drugs in a single co-
formulated tablet with once-daily dosing make this an attractive
regimen for initiation of antiretroviral therapy in resource-
constrained settings by the criteria outlined in UNAIDS
Treatment 2.0 [1].
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Background. Despite the enormous gains in reducing HIV-
related illness and death over the past decade, there are still
considerable challenges to meeting the global goal of
universal access to highly active antiretroviral treatment—a
combination of effective drugs that attack the HIV virus in
various ways—to everyone living with HIV/AIDS who could
benefit from treatment. In recognition of the related financial,
technical, and system obstacles to providing universal access
to HIV treatment, in 2010 the UN agency responsible for HIV/
AIDS—UNAIDS—launched an ambitious plan called Treat-
ment 2.0, which aims to simplify the way HIV treatment is
currently provided. One of the main focuses of Treatment 2.0
is to simplify drug regimes for the treatment of HIV and to
make treatment regimes less toxic. In line with Treatment 2.0,
the World Health Organization currently recommends that
antiretroviral regimens for the initial treatment of HIV should
include two nucleoside reverse transcriptase inhibitors (zido-
vudine or tenofovir disoproxil fumarate [DF] with lamivudine
or emtricitabine) and a non-nucleoside reverse transcriptase
inhibitor (efavirenz or nevirapine.)
Why Was This Study Done? Most of the evidence about
the safety and effectiveness of clinical trials come from
clinical trials in high-income countries and thus is not
generally representative of the majority of people with HIV.
So in this study, the researchers conducted a randomized
controlled trial in diverse populations in many different
settings to investigate whether antiretroviral regimens
administered once daily were as effective as twice-daily
regimens and also whether a regimen containing the drug
atazanavir administered once daily was as safe and effective
as a regimen containing efavirenz—data from previous
studies have suggested that atazanavir has characteristics,
such as its side effect profile, which may make it more
suitable for low income settings.
What Did the Researchers Do and Find? The researchers
recruited eligible patients from centers in Brazil, Haiti, India,
Malawi, Peru, South Africa, Thailand, the United States, and
Zimbabwe—almost half (47%) were women. Then the
researchers randomly assigned participants to one of three
regimens: efavirenz 600 mg daily plus co-formulated lami-
vudine-zidovudine 150 mg/300 mg twice daily (EFV+3TC-
ZDV); or atazanavir 400 mg once daily, plus didanosine-EC
400 mg once daily, plus emtricitabine 200 mg once daily
(ATV+DDI+FTC); or efavirenz 600 mg once daily plus
coformulated emtricitabine-tenofovir-DF 200 mg/300 mg
once daily (EFV+FTC-TDF). During the study period ATV+D-
DI+FTC was found to be inferior to EFV+3TC-ZDV, so the
Multinational Data Safety Monitoring Board ordered this arm
of the trial to stop. Then a year later, due to the low number
of treatment failures (deaths, severe HIV disease, or serious
opportunistic infections) in the remaining two arms, the
board advised the trial to stop early. So the researchers
analyzed the data obtained up to this point and pooled the
results from all of the centers.
The researchers found that during an average of 184 weeks
of follow-up, there were 95 treatment failures (18%) among
526 participants taking EFV+FTC-TDF compared to 98 failures
among 519 participants taking EFV+3TC-ZDV. During an
average 81 weeks follow-up, there were 108 failures (21%)
among 526 participants assigned to ATV+DDI+FTC and 76
(15%) among 519 participants assigned to EFV+3TC-ZDV. As
for safety, 243 (46%) participants assigned to EFV+FTC-TDF
reached a safety endpoint (grade 3 disease, abnormal lab
measurement, or the need to change drug) compared to 313
(60%) in the EFV+3TC-ZDV group. Importantly, the research-
ers found that there was greater risk of safety events for
women assigned to EFV+3TC-ZDV and also that the
atazanavir-based regimen had a higher relative efficacy in
women compared to men.
What Do These Findings Mean? These findings suggest
that in diverse populations, EFV+FTC-TDF is as effective as
EFV+3TC-ZDV but importantly, the once-daily dosing of
EFV+FTC-TDF makes this regimen useful for the initial
treatment of HIV, especially in low-income countries.
Therefore, as per the guidance in Treatment 2.0, EFV+FTC-
TDF in a single combination tablet that can be taken once a
day is an attractive option. These findings also indicate that
as ATV+DDI+FTC was found to be inferior to the other
regimens, this combination should not be used in the initial
treatment of HIV. These findings also add to the evidence
that antiretroviral efficacy and safety can differ between
women and men and support further development of sex-
specific recommendations for antiretroviral regimen options.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001290.
N The UNAIDS website has more information about
Treatment 2.0; and the WHO website provides technical
information
N For an introduction to the treatment of HIV/AIDS see
http://www.avert.org/treatment.htm; the AVERT site also
has personal stories from women living with HIV/AIDS
N AIDSmap provides information for individuals and
communities affected by HIV/AIDS
N The ACTG website provides information about research to
improve treatment of HIV and related complications
Evaluation of Antiretrovirals in Diverse Settings
PLOS Medicine | www.plosmedicine.org 16 August 2012 | Volume 9 | Issue 8 | e1001290